[go: up one dir, main page]

SI0964677T1 - Podaljsana analgezija, dosezena s transdermalnim dajanjem buprenorfina - Google Patents

Podaljsana analgezija, dosezena s transdermalnim dajanjem buprenorfina

Info

Publication number
SI0964677T1
SI0964677T1 SI9830859T SI9830859T SI0964677T1 SI 0964677 T1 SI0964677 T1 SI 0964677T1 SI 9830859 T SI9830859 T SI 9830859T SI 9830859 T SI9830859 T SI 9830859T SI 0964677 T1 SI0964677 T1 SI 0964677T1
Authority
SI
Slovenia
Prior art keywords
buprenorphine
transdermal delivery
sustained analgesia
analgesia achieved
sustained
Prior art date
Application number
SI9830859T
Other languages
English (en)
Inventor
Robert F Reder
Paul D Goldenheim
Robert F Kaiko
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26715643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0964677(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of SI0964677T1 publication Critical patent/SI0964677T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)
SI9830859T 1997-02-24 1998-02-24 Podaljsana analgezija, dosezena s transdermalnim dajanjem buprenorfina SI0964677T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3891997P 1997-02-24 1997-02-24
US08/939,068 US5968547A (en) 1997-02-24 1997-09-29 Method of providing sustained analgesia with buprenorphine
EP98906678A EP0964677B1 (en) 1997-02-24 1998-02-24 Sustained analgesia achieved with transdermal delivery of buprenorphine
PCT/US1998/003584 WO1998036728A2 (en) 1997-02-24 1998-02-24 Sustained analgesia achieved with buprenorphine

Publications (1)

Publication Number Publication Date
SI0964677T1 true SI0964677T1 (sl) 2006-12-31

Family

ID=26715643

Family Applications (3)

Application Number Title Priority Date Filing Date
SI9830859T SI0964677T1 (sl) 1997-02-24 1998-02-24 Podaljsana analgezija, dosezena s transdermalnim dajanjem buprenorfina
SI9830937T SI2305194T1 (sl) 1997-02-24 1998-02-24 Transdermalni obliž z buprenorfinom za uporabo pri zdravljenju bolečine za dozirni interval najmanj 7 dni
SI9830933T SI1570823T1 (sl) 1997-02-24 1998-02-24 Transdermalni obliž z buprenorfinom za uporabo pri zdravljenju bolečine za dozirni interval najmanj štirih dni

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI9830937T SI2305194T1 (sl) 1997-02-24 1998-02-24 Transdermalni obliž z buprenorfinom za uporabo pri zdravljenju bolečine za dozirni interval najmanj 7 dni
SI9830933T SI1570823T1 (sl) 1997-02-24 1998-02-24 Transdermalni obliž z buprenorfinom za uporabo pri zdravljenju bolečine za dozirni interval najmanj štirih dni

Country Status (21)

Country Link
US (15) US5968547A (sl)
EP (9) EP2305191A1 (sl)
JP (1) JP2000511936A (sl)
KR (1) KR100703101B1 (sl)
CN (2) CN1252705A (sl)
AT (3) ATE556682T1 (sl)
AU (2) AU2004218685B2 (sl)
BR (1) BR9815439A (sl)
CA (1) CA2276170C (sl)
CZ (2) CZ299414B6 (sl)
DE (2) DE05011213T1 (sl)
DK (4) DK1731152T3 (sl)
ES (4) ES2423925T3 (sl)
HU (3) HUP1500370D0 (sl)
IL (4) IL131561A0 (sl)
NO (11) NO322515B1 (sl)
NZ (1) NZ337386A (sl)
PL (1) PL196086B1 (sl)
PT (4) PT1731152E (sl)
SI (3) SI0964677T1 (sl)
WO (1) WO1998036728A2 (sl)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020114827A1 (en) * 1995-07-28 2002-08-22 Jie Zhang Methods and apparatus for improved administration of analgesics
US20040265353A1 (en) * 1995-07-28 2004-12-30 Zars, Inc. Systems and methods for treating panic attacks
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
PT1685839E (pt) 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
WO2001058447A1 (en) 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
IL151058A0 (en) * 2000-02-08 2003-04-10 Euro Celtique Sa Controlled-release compositions containing opioid agonist and antagonist
EP1280485A4 (en) * 2000-02-29 2006-11-29 Zars Inc TRANSDERMAL STAMP FOR IMPROVED MEDICINE
KR100452972B1 (ko) * 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
AU2001262683A1 (en) * 2000-06-02 2001-12-17 Teijin Limited Buprenorphine-containing patch
GB0021317D0 (en) * 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
DK1335689T3 (da) 2000-10-23 2010-06-14 Euro Celtique Sa System til transdermal indgivelse af loratadin og anvendelse deraf
DE60134656D1 (de) * 2000-10-23 2008-08-14 Euro Celtique Sa Hilfsmittel und methoden zur transdermalen applikation von felodipin
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
JP2004525960A (ja) * 2001-02-16 2004-08-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 尿失禁、特に切迫尿失禁の治療用経皮デリバリーディバイスの製造にブプレノルフィンを使用する方法
NZ528064A (en) * 2001-02-16 2006-03-31 Gruenenthal Chemie Utilization of buprenorphine in urinary incontinence therapy
RU2003129531A (ru) * 2001-03-02 2005-04-10 ЕВРО-КЕЛТИК Эс. Эй. (LU) N-бут-3-енил-норбупренорфин и способы его применения
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
WO2003002100A1 (en) * 2001-06-26 2003-01-09 Farrell John J Tamper-proof narcotic delivery system
AU2002316738B2 (en) 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
WO2003014247A1 (fr) * 2001-08-10 2003-02-20 Cosmed. Co., Ltd. Adhesif autocollant destine a la peau et rubans ou feuilles destines a la peau et produits a l'aide de cet autocollant
WO2003051363A1 (en) * 2001-12-17 2003-06-26 Aryx Therapeutics Analgesic delivery systems and methods of use
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
AU2003224742A1 (en) * 2002-03-20 2003-10-08 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
PT2425824T (pt) 2002-04-05 2017-08-23 Mundipharma Farmacêutica Lda Preparação farmacêutica contendo oxicodona e naloxona
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US7736665B2 (en) * 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
AU2003251482A1 (en) 2002-06-10 2003-12-22 Euro-Celtique, S.A. Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
AU2003283055A1 (en) * 2002-08-09 2004-02-25 Grunenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
AU2003268144A1 (en) * 2002-08-20 2004-03-11 Euro-Celtique, S.A. Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
CA2498798A1 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
WO2004039317A2 (en) * 2002-10-25 2004-05-13 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
JP5054893B2 (ja) * 2002-12-13 2012-10-24 ユーロ−セルティーク エス．エイ． 鎮痛のためのブプレノルフィン経皮投与計画
AU2003297074A1 (en) * 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
EP1913938A1 (en) 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US7879357B2 (en) * 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
MXPA05011703A (es) 2003-04-30 2006-01-23 Purdue Pharma Lp Forma de dosis transdermica resistente a los retardadores que comprende un componente de agente activo y un componente de agente adverso en el sitio distal de la capa del agente activo.
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
WO2004103317A2 (en) * 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
EP1638492B1 (en) * 2003-07-25 2008-01-02 Euro-Celtique S.A. Preoperative treatment of post operative pain
ATE375149T1 (de) 2003-07-25 2007-10-15 Euro Celtique Sa Behandlung von entzug
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
EP1718258B1 (en) 2004-02-23 2009-03-25 Euro-Celtique S.A. Abuse resistance opioid transdermal delivery device
US7220842B2 (en) 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP3326617A1 (en) 2004-06-12 2018-05-30 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
EP1743638A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9289583B2 (en) * 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
WO2007120747A2 (en) * 2006-04-13 2007-10-25 Nupathe Inc. Transdermal methods and systems for the delivery of anti-migraine compounds
PT2484346T (pt) 2006-06-19 2017-04-26 Alpharma Pharmaceuticals Llc Composições farmacêuticas
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
DE102006054732B4 (de) * 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
KR20090125748A (ko) * 2007-04-02 2009-12-07 토요 보세키 가부시기가이샤 대상포진 후 신경통 치료용 정제 및 대상포진 후 신경통의 치료 방법
KR101606944B1 (ko) * 2007-08-07 2016-03-28 아셀알엑스 파마슈티컬스 인코퍼레이티드 경구 경점막 투여형을 사용한 시술시 진정과 무통을 위한 조성물 및 방법
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2009114118A2 (en) * 2008-03-08 2009-09-17 Theraquest Biosciences, Inc. Oral pharmaceutical compositions of buprenorphine and method of use
CN105833420A (zh) * 2008-06-23 2016-08-10 生物递送科学国际公司 多向粘膜给药装置及使用方法
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
ME03298B (me) 2009-03-10 2019-07-20 Euro Celtique Sa Farmaceutske kombinacije sa trenutnim oslobađanjem које obuhvataju oksikodon i nalokson
WO2010107761A1 (en) 2009-03-18 2010-09-23 Acelrx Pharmaceuticals, Inc. Improved storage and dispensing devices for administration of oral transmucosal dosage forms
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US20110037455A1 (en) * 2009-08-17 2011-02-17 Oren Navot System for measuring electrical power
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US9168251B2 (en) * 2010-09-03 2015-10-27 Zoetis Belgium S.A High dose buprenorphine compositions and use as analgesic
WO2012048455A1 (zh) * 2010-10-12 2012-04-19 武汉大学 一种抗病毒透皮吸收贴片及其制备方法
CN103200944B (zh) * 2010-11-17 2016-05-04 赫克萨尔股份公司 包含丁丙诺啡的经皮治疗系统
DE102011076653A1 (de) 2011-05-27 2012-11-29 Acino Ag Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
EP2758134B1 (en) 2011-09-19 2019-05-29 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
AU2012327247B2 (en) * 2011-12-12 2015-12-24 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
MX362217B (es) * 2011-12-21 2019-01-09 Biodelivery Sciences Int Inc Dispositivos de administracion de farmacos por via transmucosal para uso en el alivio del dolor cronico.
ES2663412T3 (es) * 2012-01-31 2018-04-12 Grünenthal GmbH Parche farmacéutico para la administración transdérmica de (1R,4R)-6'-fluor-N,N-dimetil-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4-b]indol]-4-amina
DE112013002074T5 (de) 2012-04-17 2015-01-29 Purdue Pharma L.P. Systeme und Methoden zur Behandlung einer Opioid-induzierten unerwünschten pharmakodynamischen Reaktion
CA2882870C (en) * 2012-08-24 2020-12-15 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
CN104955516B (zh) * 2012-12-28 2019-01-22 帝国制药美国公司 延长丁丙诺啡经皮递送组合物及其使用方法
DE112014002664T5 (de) 2013-06-04 2016-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales Verabreichungssystem
CN105517551A (zh) 2013-07-23 2016-04-20 欧洲凯尔特公司 用于在患有疼痛和导致肠生态失调和/或提高肠细菌移位风险之疾病的患者中治疗疼痛的羟考酮与纳洛酮的组合
DE102014013448A1 (de) 2014-09-16 2016-03-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales Therapeutisches System umfassend Buprenorphin
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
SG11201704797TA (en) 2014-12-23 2017-07-28 Acelrx Pharmaceuticals Inc Systems, devices and methods for dispensing oral transmucosal dosage forms
US9656441B2 (en) 2015-01-08 2017-05-23 Alfred E. Tiefenbacher ( Gmbh & Co. Kg) Transdermal patch
CA3104099A1 (en) 2015-03-10 2016-09-15 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
JP2020526500A (ja) 2017-06-30 2020-08-31 パーデュー、ファーマ、リミテッド、パートナーシップ 治療方法及びその剤形
CN111971032A (zh) * 2018-03-13 2020-11-20 罗曼治疗系统股份公司 包含有机硅丙烯酸杂化聚合物的透皮治疗系统
US11388516B2 (en) * 2019-02-07 2022-07-12 Thomas STACHURA Privacy device for smart speakers
US10586540B1 (en) * 2019-06-12 2020-03-10 Sonos, Inc. Network microphone device with command keyword conditioning
US11288972B2 (en) 2019-12-19 2022-03-29 Textron Innovations Inc. Fleet controller
WO2021163529A2 (en) * 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Methods of treatment with buprenorphine
CZ37580U1 (cs) 2022-03-02 2023-12-21 RECUTECH s.r.o Teplo-vlhkosměnná deska a entalpický výměník
AU2024243584A1 (en) * 2023-04-07 2025-11-20 Sleep Solutions Of Texas, Llc Mucosal form for drug delivery through the mucosa and methods of treatment with same

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4058599A (en) 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
US4262003A (en) * 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
US4060084A (en) * 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4119713A (en) 1977-02-09 1978-10-10 Sam Carosio Analgesic and anti-inflammatory composition
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
DE3330750A1 (de) * 1983-08-26 1985-03-14 Chemische Werke Hüls AG, 4370 Marl Verfahren zur erzeugung von acetylen und synthese- oder reduktionsgas aus kohle in einem lichtbogenprozess
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4636539A (en) 1984-01-30 1987-01-13 Loctite (Ireland) Limited Instant adhesive composition utilizing calixarene accelerators
US4601893A (en) 1984-02-08 1986-07-22 Pfizer Inc. Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
DE3546830C2 (de) 1984-07-23 1995-07-20 Alza Corp Transdermales Abgabesystem zur Verabreichung von Fentanyl
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4834978A (en) 1984-10-01 1989-05-30 Biotek, Inc. Method of transdermal drug delivery
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4698062A (en) 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
JPS62298530A (ja) 1986-06-16 1987-12-25 Otsuka Pharmaceut Co Ltd 坐薬用医薬組成物
USRE33093E (en) 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US4938759A (en) 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US5091405A (en) * 1987-01-05 1992-02-25 E. I. Du Pont De Nemours And Company Insecticidal pyrazolines
US5171576A (en) 1987-03-09 1992-12-15 Alza Corporation Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
DE3812481A1 (de) * 1987-08-26 1989-03-09 Bayer Ag Wasserhaertende polymerzubereitung
US4915954A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4983395A (en) * 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4994278A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Breathable backing
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
US5336210A (en) * 1989-02-28 1994-08-09 Teijin Limited Plaster agent
US5028435A (en) 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DE3939376C1 (sl) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
EP0432945A1 (en) 1989-12-12 1991-06-19 Warner-Lambert Company A transdermal delivery system for treatment of cocaine and heroin addiction
JP2849937B2 (ja) * 1990-04-18 1999-01-27 日東電工株式会社 医療用貼付剤
ATE131384T1 (de) * 1990-04-24 1995-12-15 Teijin Ltd Pflaster
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
DE4020144A1 (de) * 1990-06-25 1992-01-09 Lohmann Therapie Syst Lts Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen
US5688547A (en) 1990-08-03 1997-11-18 American Cyanamid Company Meal replacement composition and method of weight control
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
CN1036343C (zh) 1990-11-10 1997-11-05 天津市计划生育研究所 新促黄体生成素释放激素拮抗类似物的制备方法
PL166095B1 (pl) 1991-04-03 1995-03-31 Warszawskie Zaklady Farma Sposób wytwarzania N-cyklopropylometylo-7a -[(S)-1-hydroksy-1,2,2-trimetylopropylo] endo-etano-6,7,8,14-tetrahydronororipaviny
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
AU657973B2 (en) 1991-05-07 1995-03-30 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5225440A (en) * 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
US5229130A (en) 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5272149A (en) 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
WO1993023019A1 (en) 1992-05-11 1993-11-25 Sri International Transdermal drug delivery systems and related compositions and methods of use
ATE185694T1 (de) 1992-05-13 1999-11-15 Alza Corp Oxybutynin zur transdermalen verabreichung
CA2135925C (en) 1992-06-11 2001-04-10 Werner E. Heiber Use of glycerin in moderating transdermal drug delivery
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
DE4237453C1 (sl) 1992-11-06 1993-08-19 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
JP3489831B2 (ja) * 1993-04-20 2004-01-26 ヘクサル・アクチエンゲゼルシャフト 活性成分パッチ
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
JPH08512054A (ja) 1993-06-25 1996-12-17 アルザ・コーポレーション 経皮系におけるポリ−ｎ−ビニルアミドの含有
AU7566994A (en) 1993-08-16 1995-03-14 Cygnus Therapeutic Systems Contact adhesive extends wear time on skin
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
EP0739352A1 (en) 1994-01-20 1996-10-30 Akzo Nobel N.V. New composition of glycoprotein isoforms having follicle stimulating activity
JPH07206710A (ja) * 1994-01-21 1995-08-08 Nitto Denko Corp 経皮投薬用テープ製剤
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
JP2819236B2 (ja) * 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5468457A (en) 1994-12-22 1995-11-21 Osram Sylvania Inc. Method of making tungsten-copper composite oxides
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
WO1997004835A1 (de) 1995-07-28 1997-02-13 Novartis Ag Transdermales system
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
FR2739731B1 (fr) 1995-10-09 1998-01-02 Axon Cable Sa Procede de raccordement de micro-cables coaxiaux aux pistes d'un circuit imprime
DE19642043A1 (de) * 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
US5792740A (en) 1996-03-08 1998-08-11 Firmenich Sa Fragrant macrocyclic lactones
HUP9902673A3 (en) 1996-03-25 2001-04-28 Lohmann Therapie Syst Lts Transdermal therapeutic system with small application-area thickness and great flexibility, and production process
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
US6271240B1 (en) 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
EP0821957A3 (en) 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
US20010006677A1 (en) 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
AT405158B (de) * 1996-12-04 1999-06-25 Steyr Daimler Puch Ag Verfahren zur selbsttätigen steuerung der sperrkupplungen eines allradgetriebenen fahrzeuges und fahrzeug mit knicklenkung und sperrbaren differentialen
US6787149B1 (en) 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
DE19652188C2 (de) 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
JP2001512440A (ja) 1997-02-07 2001-08-21 セラテック・インコーポレーテッド テストステロンの欠乏症状を持つ女性のテストステロン補充のための組生物および方法
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
WO1998048811A1 (en) 1997-04-30 1998-11-05 Human Pheromone Sciences, Inc. Method of fixing fragrances in fragrance composition and other compositions
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US5900420A (en) 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
GB2328443B (en) 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
DE19738855C2 (de) 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US7011843B2 (en) 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
US6242456B1 (en) 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
JP4425465B2 (ja) 1998-03-23 2010-03-03 エラン コーポレーション ピーエルシー 薬剤送給装置
ES2237104T3 (es) 1998-04-29 2005-07-16 Virotex Corporation Dispositivo portador de productos farmaceuticos adecuado para el aporte de compuestos farmaceuticos a superficies mucosas.
DE19840758A1 (de) 1998-09-07 2000-03-09 Liedtke Pharmed Gmbh Systemische Therapie von Schmerz- und depressiver Befindlichkeit
KR100383252B1 (ko) 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
IT1305303B1 (it) 1999-03-10 2001-05-04 Farmigea Spa Uso dell'olio essenziale di niaouli come promotore per la permeazionetransdermica.
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6554851B1 (en) 1999-05-07 2003-04-29 Scimed Life Systems, Inc. Methods of sealing an injection site
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) * 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP1315502B1 (en) 2000-08-30 2010-03-17 Unimed Pharmaceuticals, LLC Method for treating erectile dysfunction and increasing libido in men
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
RU2003129531A (ru) 2001-03-02 2005-04-10 ЕВРО-КЕЛТИК Эс. Эй. (LU) N-бут-3-енил-норбупренорфин и способы его применения
CA2441889A1 (en) 2001-03-23 2002-10-03 Albert Einstein College Of Medicine Of Yeshiva University Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
DK1424973T3 (da) * 2001-04-23 2010-06-14 Euro Celtique Sa Bortskaffelsessystem til transdermal doseringsform
DK1397095T3 (da) 2001-05-01 2009-03-09 Euro Celtique Sa Misbrugsresistente, opioid-holdige transdermale systemer
DK1390866T3 (da) 2001-05-22 2010-05-10 Euro Celtique Sa Beholder og fremgangsmåde til afgivelse af transdermale doseringsformer
RU2003135208A (ru) 2001-06-04 2005-05-10 Квинетик Лимитед (Gb) Способ формирования рисунка
WO2003009805A2 (en) 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
WO2003037313A2 (en) 2001-10-31 2003-05-08 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
AU2003224742A1 (en) 2002-03-20 2003-10-08 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
EP1422230B1 (en) 2002-11-25 2007-12-26 Chi Mei Foundation Medical Center Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgestic pharmaceutical compositions
AU2003297074A1 (en) * 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
JP5054893B2 (ja) 2002-12-13 2012-10-24 ユーロ−セルティーク エス．エイ． 鎮痛のためのブプレノルフィン経皮投与計画
WO2004103317A2 (en) 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
EP1638492B1 (en) 2003-07-25 2008-01-02 Euro-Celtique S.A. Preoperative treatment of post operative pain
ATE375149T1 (de) 2003-07-25 2007-10-15 Euro Celtique Sa Behandlung von entzug
WO2005018565A2 (en) 2003-08-21 2005-03-03 Transoral Pharmaceuticals, Inc. Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
KR20080007449A (ko) 2005-05-03 2008-01-21 이노젠, 인크. 영양 보충물의 경점막 전달을 위한 식용 필름
WO2007070632A2 (en) 2005-12-13 2007-06-21 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US20080096900A1 (en) 2006-06-26 2008-04-24 Amgen Inc. Methods for treating atherosclerosis
SI2054031T1 (sl) 2006-07-21 2016-09-30 Biodelivery Sciences International, Inc. Transmukozne naprave za administracijo z izboljšanim vnosom
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
EP2248519B1 (en) 2006-10-02 2017-12-06 Apr Applied Pharma Research S.A. Non-mucoadhesive film dosage forms
WO2008042508A1 (en) 2006-10-03 2008-04-10 University Of Southern California Grp78 as a predictor of responsiveness to therapeutic agents
GB2447016A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
US20080226702A1 (en) 2007-03-16 2008-09-18 Endo Pharmaceuticals, Inc. Transdermal Delivery Form Disposal Systems and Methods
CN105833420A (zh) 2008-06-23 2016-08-10 生物递送科学国际公司 多向粘膜给药装置及使用方法
CN103200944B (zh) 2010-11-17 2016-05-04 赫克萨尔股份公司 包含丁丙诺啡的经皮治疗系统

Also Published As

Publication number Publication date
CN1827107B (zh) 2010-05-26
DE69835584D1 (de) 2006-09-28
NO334290B1 (no) 2014-01-27
NO20064395L (no) 1999-10-22
NO994087D0 (no) 1999-08-24
PL335306A1 (en) 2000-04-10
ATE556682T1 (de) 2012-05-15
US9642850B2 (en) 2017-05-09
NO20131533L (no) 1999-10-22
CZ300999A3 (cs) 2000-03-15
NO994087L (no) 1999-10-22
AU2004218685A1 (en) 2004-11-04
US20060216340A1 (en) 2006-09-28
ATE336212T1 (de) 2006-09-15
EP2301494A1 (en) 2011-03-30
EP2305193A1 (en) 2011-04-06
NO20074292L (no) 1999-10-22
EP2301493A1 (en) 2011-03-30
ES2271988T3 (es) 2007-04-16
SI1570823T1 (sl) 2012-03-30
CZ2015477A3 (cs) 2015-10-21
AU774779B2 (en) 2004-07-08
IL201437A (en) 2010-12-30
CZ299414B6 (cs) 2008-07-16
EP1570823A3 (en) 2006-01-18
EP0964677A4 (en) 2002-12-18
IL131561A0 (en) 2001-01-28
EP1731152A2 (en) 2006-12-13
PT1570823E (pt) 2012-03-02
WO1998036728A3 (en) 1998-12-10
US20030198675A1 (en) 2003-10-23
HU230374B1 (hu) 2016-03-29
US20130197020A1 (en) 2013-08-01
HK1096847A1 (en) 2007-06-15
CN1252705A (zh) 2000-05-10
NO20120563L (no) 1999-10-22
PT1731152E (pt) 2013-07-31
US20010002259A1 (en) 2001-05-31
DK1731152T3 (da) 2013-07-22
ES2423925T3 (es) 2013-09-25
NO337094B1 (no) 2016-01-18
US20170056393A1 (en) 2017-03-02
EP0964677B1 (en) 2006-08-16
NO20101190L (no) 1999-10-22
NO333139B1 (no) 2013-03-11
HK1103621A1 (en) 2007-12-28
CN1827107A (zh) 2006-09-06
EP0964677A1 (en) 1999-12-22
EP2305191A1 (en) 2011-04-06
NO20151450A1 (no) 1999-10-22
HUP0002342A2 (hu) 2000-12-28
NO322515B1 (no) 2006-10-16
DK1570823T3 (da) 2012-02-20
HU230608B1 (hu) 2017-03-28
NO333374B1 (no) 2013-05-13
IL131561A (en) 2010-05-31
PT964677E (pt) 2006-12-29
PL196086B1 (pl) 2007-12-31
DK0964677T3 (da) 2006-12-11
USRE41408E1 (en) 2010-06-29
EP1570823A2 (en) 2005-09-07
CA2276170C (en) 2007-12-04
EP1731152A3 (en) 2007-11-14
US20160220559A1 (en) 2016-08-04
JP2000511936A (ja) 2000-09-12
EP2305194B1 (en) 2012-05-09
NZ337386A (en) 2001-06-29
KR20000075648A (ko) 2000-12-26
US20150157625A1 (en) 2015-06-11
BR9815439A (pt) 2001-10-16
AU743071B2 (en) 2002-01-17
USRE41489E1 (en) 2010-08-10
NO20130298L (no) 1999-10-22
EP1570823B1 (en) 2011-12-28
ATE538765T1 (de) 2012-01-15
HUP0002342A3 (en) 2001-04-28
EP2305192A1 (en) 2011-04-06
SI2305194T1 (sl) 2012-10-30
US6344212B2 (en) 2002-02-05
AU2004218685B2 (en) 2009-01-22
EP1731152B1 (en) 2013-05-01
US20030091631A1 (en) 2003-05-15
ES2380023T3 (es) 2012-05-07
KR100703101B1 (ko) 2007-04-06
DK2305194T3 (da) 2012-08-13
AU2008261134A1 (en) 2009-01-15
AU2925402A (en) 2002-05-16
US6231886B1 (en) 2001-05-15
NO340067B1 (no) 2017-03-06
NO329734B1 (no) 2010-12-13
IL207067A (en) 2011-12-29
US20110288112A1 (en) 2011-11-24
ES2387752T3 (es) 2012-10-01
NO329838B1 (no) 2011-01-10
WO1998036728A2 (en) 1998-08-27
NO2017011I1 (no) 2017-04-04
US20140073663A1 (en) 2014-03-13
CA2276170A1 (en) 1998-08-27
NO332248B1 (no) 2012-08-06
NO20111441L (no) 1999-10-22
HUP1500370D0 (hu) 2000-12-28
DE69835584T2 (de) 2007-08-16
US5968547A (en) 1999-10-19
AU6184198A (en) 1998-09-09
PT2305194E (pt) 2012-08-14
NO2016013I1 (no) 2016-07-18
USRE41571E1 (en) 2010-08-24
HK1153377A1 (en) 2012-03-30
DE05011213T1 (de) 2007-09-06
AU2008261134B2 (en) 2012-08-02
EP2305194A1 (en) 2011-04-06
HUP1200599A2 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
SI0964677T1 (sl) Podaljsana analgezija, dosezena s transdermalnim dajanjem buprenorfina
IL124629A0 (en) Transdermal device for the delivery of flurbiprofen
EP0592569A4 (en) COMPOSITION AND METHOD FOR TRANSDERMAL ADMINISTRATION OF DICLOFENAC.
IL127189A0 (en) Compositions methods and devices for the transdermal delivery of drugs
HUP9802983A3 (en) Composition for transdermal delivery
ZA964858B (en) Nozzle for delivering liquid/gas mixture.
CA2270177A1 (en) Transdermal administration of ment
MY118828A (en) Substituted amino compounds and their use as substances having an analgesic effect
AU3772989A (en) Penetration enhancers for transdermal delivery of systemic agent
AU4650596A (en) Composition and methods for transdermal delivery of acid-labile drugs
AU2559995A (en) Transdermal delivery of anti-epileptic drugs
IL141055A0 (en) Pharmaceutical composition comprising ibuprofen and domperidone
AU3170697A (en) Transdermal drug delivery device for the delivery of tropisetron or granisetron
EP0906757A3 (en) Analgesic composition comprising moxonidine and an opioid analgesic agent
AU3723695A (en) Transdermal device for delivery of levonorgestrel
AU1143899A (en) Transdermal delivery of 3,4-diarylchromans
AU1305999A (en) (+)-ephedrine as a sympathomimetic drug
AU5878598A (en) Device for enriching the oxygen rate of combustion mixtures
PL332035A1 (en) Transdermal therapeutic system including an estriol-containing composition of active substances
HUP9901162A3 (en) Compounds and compositions for delivering active agents
HU9602061D0 (en) Agent, intended for transdermal administration, containing 14alfa, 17alfa-ethanoestra-1,3,5(10)-triene-3,17beta-diol
AU5887896A (en) Nozzle for delivering liquid/gas mixture
MX9709013A (es) Forma de dosis que comprende oxibutinina.